News
-
CoImmune, Inc. Announces Closing of $45 Million Series A Financing
CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the closing of a $45M Series A financing. CoImmune will use the proceeds from the financing to fund its ongoing Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma and multiple …
CoImmune, Inc. Announces Closing of $45 Million Series A Financing Read More »
-
CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma. With the merger’s …
-
CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a Phase 2b clinical trial in advanced metastatic renal cell carcinoma (mRCC). CMN-001, formerly known as AGS-003, is a dendritic cell-based immunotherapy custom matched to each patient’s particular disease. The rationale for …
-
CoImmune, Inc. and Formula Pharmaceuticals, Inc. announced today the merger between the two companies, bringing together two therapeutic immuno-oncology platforms. Upon completion of the merger of Formula Pharmaceuticals into CoImmune, bringing forth access to all of Formula Pharmaceuticals’ tangible and intangible assets, the merged company will continue to focus on running a Phase 2b trial …
